Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04543071 · ClinicalTrials.gov registry record · Phase 2
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
A Phase 2 study of Pancreatic Cancer and Adenocarcinoma, sponsored by Gulam Manji.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT04543071 is a Phase 2 study of Pancreatic Cancer and Adenocarcinoma that is actively recruiting participants, run by Gulam Manji. The registered enrollment target is 10 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04543071, a Phase 2 study of Pancreatic Cancer and Adenocarcinoma, is actively recruiting participants, sponsored by Gulam Manji.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. The treatment consists of standard chemotherapy (gemcitabine and nab-paclitaxel) which is FDA approved and is standard treatment for patients with pancreatic adenocarcinoma. Participants will receive immunotherapy (cemiplimab) which activates the body's immune system to attack cancer cells. Cemiplimab is FDA approved for treatment of skin cancer but not for pancreas cancer. Participants will also receive Motixafortide, a new medication which has shown in the laboratory to help immunotherapy work better. Motixafortide has been tested together with immunotherapy (Pembrolizumab), and chemotherapy (5-Fluorouracil and liposomal Irinotecan) and was deemed safe to test additional patients. Motixafortide has not been tested with the specific immunotherapy (Cemiplimab) and chemotherapy (gemcitabine and nab-paclitaxel) which participants will receive and is being tested in this clinical trial.
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG Gemcitabine
- DRUG Nab paclitaxel
- DRUG Motixafortide
Study Locations (3)
New York
- Columbia University Irving Medical Center - New York
Rhode Island
- Brown University - Providence
Wisconsin
- Medical College of Wisconsin, Wisconsin Diagnostic Labratories - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04543071
The ClinicalTrials.gov registry entry for NCT04543071 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Gulam Manji, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cemiplimab is the first listed.
NCT04543071 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Rhode Island, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04543071 about?
NCT04543071 is a clinical study titled "Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma". The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. The treatment consists of standard chemotherapy (gemcitabine ...
What is the current status of trial NCT04543071?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2020-11-09. Estimated completion is 2028-08.
What conditions does trial NCT04543071 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Adenocarcinoma, Adenocarcinoma of the Pancreas.
What interventions are being tested in trial NCT04543071?
The interventions under investigation include: Cemiplimab (DRUG), Gemcitabine (DRUG), Nab paclitaxel (DRUG), Motixafortide (DRUG).
Who is sponsoring clinical trial NCT04543071?
This trial is sponsored by Gulam Manji, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04543071 being conducted?
This trial has 3 study locations across New York, Rhode Island, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.